April 1, 2020 / 6:59 AM / 4 months ago

BRIEF-Novo Nordisk Presents Results From Saxenda Trial

April 1 (Reuters) - Novo Nordisk A/S:

* SAID ON TUESDAY SAXENDA DEMONSTRATED IMPROVEMENTS IN BMI AND BODY WEIGHT IN ADOLESCENTS WITH OBESITY

* TRIAL ACHIEVED ITS PRIMARY ENDPOINT DEMONSTRATING THAT SAXENDA, COMPARED WITH PLACEBO, WAS SUPERIOR IN REDUCING BODY MASS INDEX (BMI) STANDARD DEVIATION SCORE (SDS)

* THERE WERE NO NEW SAFETY SIGNALS IDENTIFIED, AND NO SEVERE HYPOGLYCAEMIAS WERE REPORTED, AND ADVERSE EVENTS WERE SIMILAR TO THOSE OBSERVED IN ADULTS

Source text for Eikon: [bit.ly/2xGEBX2]

Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below